Laverty joins Eisai
Prior to joining Novartis, Laverty worked in several corporate policy, corporate affairs, and product public affairs positions at Bristol-Myers Squibb Company.
The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.
Haymarket Media Group launched an American version of the publisher's Campaign UK media brand this week.
Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.